EAU 2021 | NOV202 increases olaparib efficacy in prostate cancer xenografts

Evangelia Sereti, MSc, PhD, Lund University, Malmo, Sweden, shares the findings of a preclinical study investigating the use of NOV202 in combination with olaparib in BRCA1/2-mutated prostate cancer cell xenografts. NOV202 is a novel vascular disrupting agent (VDA). Olaparib is a PARP inhibitor which has previously been shown to significantly improve the survival of patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer. The study reported that single-agent NOV202 and NOV202 in combination with olaparib both induced tumor growth inhibition in BRCA1/2-mutated xenografts. The efficacy of olaparib was found to be significantly increased with the addition of NOV202. This interview took place at the virtual European Association of Urology (EAU) Virtual Meeting 2021.